---
trial_id: 234
discovery_date: 2022-03-27 23:44:37.254829
date: 2022-03-27 23:44:37.254829
title: "B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis"
summary: |
  <b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Drug: Ocrelizumab<br /><b>Sponsor</b>:    VU University Medical Center<br /><b>Not yet recruiting</b>
link: 'https://clinicaltrials.gov/ct2/show/NCT05296161?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14'
published_date: 2022-03-25 16:00:00
trial_source: ClinicalTrials.gov
relevant: 
options:
  unlisted: false
---
<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Drug: Ocrelizumab<br /><b>Sponsor</b>:    VU University Medical Center<br /><b>Not yet recruiting</b>